Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.[2][3]
History
The company was founded in 2007 as Genesis Biopharma. In 2013, Lion merged with Genesis Biopharma аnd became Lion Bio Pharma,[4] which was then rebranded to Iovance in 2017.[5]
In 2024, the US FDA gave accelerated approval to Lifileucel, marketed under the brand name Amtagavi. the company's tumor-infiltrating lymphocyte drug for the treatment of unresectable or metastatic melanoma.[6]